Semaglutide Reduced Risk for Major Kidney Disease Events by 24% for Patients with Type 2 Diabetes and Kidney Disease

Posted on by

American Diabetes Association Symposium Showcases New Potential Solution for Patients at High-Risk of Kidney Outcomes ORLANDO, Fla., June 24, 2024 /PRNewswire/ — Today, findings from the landmark FLOW trial, the first dedicated kidney outcomes trial with a GLP-1 (glucagon-like peptide-1)…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.